Lilly/BI biosimilar Lantus approved in Europe

Sanofi's blockbuster long-lasting insulin, Lantus, faces market erosion in Europe following the approval there of a biosimilar version from Lilly and Boehringer Ingelheim. Their insulin glargine product, with the provisional brand name Abasria, is the first insulin treatment to be approved through the European Medicines Agency's biosimilar pathway.